$85 Million Premises Liability Verdict | Here goes a short description of the case (maybe the title) and a link to read more (optional)

Children’s Hospital of Philadelphia funded by FDA to study possible neurological effects of MiriLAX on children under seventeen

Miralax Logo

Since 2014, the Children’s Hospital of Philadelphia (CHOP) has been conducting a study, funded by the FDA, on the disturbing effects of over-the-counter laxative, MiraLAX, on children. The hospital refuses to release any information on the study or the individual families involved until it is concluded.

The study is surrounding a chemical found in MiraLAX powder called Polyethylene glycol 3350 (PEG 3350) which can potentially degrade into ethylene glycol or diethylene glycol – both toxic ingredients found in antifreeze. In its grant description, the FDA noted that they had received a number of reports of adverse events related to children who had ingested PEG products.

“The agency has conducted a review that documented a number of reports of neurological and psychiatric events associated with chronic PEG use in children. A number of these pediatric patients received an adult dose of PEG (17 grams) for a duration ranging from a few days to a couple of years.”

On Tuesday, February 14th, Action News in Philadelphia interviewed parents of children who underwent serious neuro-psychotic changes after being prescribed Miralax as toddlers, including outbursts of manic rage and agression. These parents are not the only ones to have witnessed these changes in their children. A Facebook group titled Parents Against MiraLAX (PEG 3350) contains 4,715 members, many of whom joined to share similar experiences and voice concerns about the potentially toxic ingredient found in MiraLAX.

Philadelphia Personal Injury Attorneys at Messa & Associates

While there is no class action lawsuit filed to date, Philadelphia Products Liability Attorneys are reviewing potential MiraLAX cases. If you have questions about possible legal recourse caused by MiriLAX, or any other drug products or medical devices, call a products liability attorney at Messa & Associates. The team of Philadelphia personal injury attorneys at Messa & Associates is highly experienced in handling dangerous medical malpractice, drug, and medical device cases. the firm has earned multiple seven-, eight-, and nine-figure verdicts and settlements for clients injured by defective drugs, including Topamax mass tort cases in Philadelphia that earned over $14 million for victims of Topamax-related birth defects.

Messa & Associates is armed with the right attorneys and the necessary connections to successfully litigate defective drug and medical device claims. If you or a loved one has suffered from these disturbing effects of MiraLAX, contact an attorney from Messa & Associates. Call 1-877-MessaLaw for a free consultation or submit an online inquiry for a free case evaluation.

About the Author

Joe Messa

Joe MessaJoe Messa is the founder of Messa & Associates, a results-oriented personal injury law firm comprised of New Jersey and Philadelphia attorneys who specialize in medical malpractice, product liability, catastrophic injury, motor vehicle accidents, brain injury, birth injury, and burns, fires, and explosions. Messa & Associates holds a distinguished record of multi-million dollar verdicts and settlements for catastrophically injured clients, including but certainly not limited to: a $120 million Products Liablity settlement, an $85 million Premises Liability verdict, a $35 million Work Injury settlement, a $28.7 million Motor Vehicle Accident verdict, and a $16.5 million Medical Malpractice verdict.View all posts by Joe Messa →

Leave a Reply

Philadelphia | Downingtown | Conshohocken | Cherry Hill | Collingswood | Linwood | Roselle